We craft small-molecule therapeutics for neurodegenerative
diseases by harnessing the power of distributed knowledge, the tools
of discovery informatics, and a holistic approach to drug discovery.

BSIM˛ is at the forefront of computing technologies to discover the drugs of the future.

Streamlining drug discovery through:
/ Cheminformatics
/ Structural Bioinformatics
/ Network and Systems Pharmacology and cutting-edge hardware

Integrating all discovery stages with Academia and CROs, for:
/ Chemical synthesis
/In vitro and in vivo proof-of-concept
/ Pharmaceutical development

Making drug candidates against neurodegenerative diseases, tailored for:
/ High efficacy
/ Highest safety
/ Optimal properties for long-term therapies


BSIM˛ is building a portfolio of drug candidates against fatal or impairing neurodegenerative diseases. The fist product in the pipeline is directed to a rare, fatal peripheral neuropathy — Familial Amyloid Polyneuropathy (FAP). The discovery and optimization of lead compounds holding pharmacological properties unmatched by any known inhibitor of transthyretin-related amyloid offers promise for safe treatments of FAP, FAC (Familial Amyloid Cardiomyopathy), and other transthyretin-related amyloidoses.

Compared with the only solution in the market, our candidates display critical advantages:

/ Strongest in vitro inhibitory activity against amyloid formation;
/ Lowest cytotoxicity in cell viability assays;
/ Optimal physicochemical properties for long-term therapies.

Increased longevity and quality of life are ancient longings of human societies, but never like today were they so pressing. Human ageing and agerelated diseases show increasing trends and represent today one of the biggest challenges facing Society and the pharmaceutical industry. BSIM² potential customers are Pharma and Biotech companies willing to replenish their portfolios with novel therapies against:

/ Rare, fatal or impairing amyloidoses like Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) — affecting ca. 50,000 patients worldwide;

/ Age-related diseases like Senile Systemic Amyloidosis, Parkinson’s disease and Alzheimer’s disease — altogether affecting more than 30 million people worldwide.

BSIM² is currently seeking a joint-venture agreement to continue product development, or alternatively an IP licensing agreement of the company’s first products to fight FAP. BSIM² is the sole owner of the commercial rights of the IP relating to the compounds in development for the treatment of transthyretin-related amyloidoses.

The target market of FAP alone has been estimated in excess of 1 billion US dollars.

  Contact Name: Rui M. Brito

Biocant Park, Parque Tecnológico de
Cantanhede, Núcleo 04, Lote 2,
3060-197 Cantanhede, Portugal

Phone: +351 231 410 892
Fax: +351 231 410 901

Share |